Wells Fargo on Soleno Therapeutics Inc. (SLNO): 'We Think Shares Should Trade Up at Least +20% on ACAD Failure'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
Go back to Wells Fargo on Soleno Therapeutics Inc. (SLNO): 'We Think Shares Should Trade Up at Least +20% on ACAD Failure'
September 24, 2025 3:41 PM EDT
Oppenheimer analyst Matthew Hershenhorn lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $21.00 (from $22.00) while maintaining a Perform rating.
The analyst comments "We anticipated a higher likelihood of ACP-101 missing the primary endpoint of the Ph3 COMPASS-PWS study, driving underperformance today... More
September 24, 2025 3:38 PM EDT
TD Cowen analyst Ritu Baral lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $35.00 (from $39.00) while maintaining a Buy rating.
The analyst comments "ACAD announced that ACP-101 (intranasal carbetocin) missed in the Ph3 Prader Willi study, failing to separate from... More
September 24, 2025 10:25 AM EDT
Leerink Partners analyst Marc Goodman reiterated an Outperform rating and $32.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
The analyst comments "Bottom Line: While disappointed that ACP-101 missed its primary endpoint, we had low expectations going into the readout, especially since it... More
September 24, 2025 10:23 AM EDT
BofA Securities analyst Tazeen Ahmad reiterated a Neutral rating and $27.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
The analyst comments "ACAD announced the ph 3 COMPASS PWS study evaluating ACP-101 (intranasal carbetocin) in patients with hyperphagia in Prader-Willi syndrome (PWS) failed to... More
September 24, 2025 9:29 AM EDT
Baird analyst Joel Beatty reiterated an Outperform rating and $31.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
The analyst comments "No change to outlook on clinical trial update. This morning, Acadia announced the Phase 3 COMPASS study of ACP-101 in PWS did not meet the... More
September 24, 2025 8:05 AM EDT
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $28.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
The analyst comments "ACP-101 miss in PWS represents a meaningful step back in Acadia's R&D development plans. Ph 3 results from the company's COMPASS... More
